Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market
Biologic patent protection in the U.S. delays biosimilar entry for 12 years, costing patients billions. Learn how the BPCIA, patent thickets, and high development costs block competition-and why biosimilars still haven’t reached most patients.